Minerva Neurosciences, Inc. (NERV) |
|
7.3 -0.15 (-2.01%)
|
09-27 16:00 |
|
Open: |
7.36 |
Pre. Close: |
7.45 |
|
High:
|
7.36 |
Low:
|
7.15 |
|
Volume:
|
8,650 |
Market Cap:
|
51(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 4:21:00 PM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
|
| Target: |
Six months: 9.98  One year: 11 |
| Support: |
Support1: 7.15 Support2: 5.94 |
| Resistance: |
Resistance1: 8.55 Resistance2: 9.42 |
| Pivot: |
7.77 |
| Moving Average: |
MA(5): 7.51 MA(20): 7.87
MA(100): 8.16  MA(250): 5.18 |
| MACD: |
MACD(12,26): -0.4 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 10.2 %D(3): 17.8 |
| RSI: |
RSI(14): 36.6 |
| 52-week: |
High: 14.69 Low: 1.25 |
| Average Vol(K): |
3-Month: 57 (K) 10-Days: 9 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NERV ] has closed above bottom band by 0.3%. Bollinger Bands are 71.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.41 - 7.48 |
7.48 - 7.52 |
|
Low:
|
7 - 7.09 |
7.09 - 7.15 |
|
Close:
|
7.19 - 7.35 |
7.35 - 7.44 |
|
Company Description |
|
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. |
Headline News |
Wed, 13 Sep 2023
Should You Buy Minerva Neurosciences Inc (NERV) Stock on Wednesday? - InvestorsObserver
Tue, 01 Aug 2023
Minerva Neurosciences Reports 2023 Second Quarter Financial ... - GlobeNewswire
Wed, 28 Jun 2023
Minerva Neurosciences to launch ~$20M private investment in ... - Seeking Alpha
Wed, 28 Jun 2023
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market - Yahoo Finance
Mon, 15 May 2023
Minerva Neurosciences Reports 2023 First Quarter Financial ... - GlobeNewswire
Wed, 10 May 2023
Minerva Neurosciences Announces Update on its New Drug ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
7 (M) |
| Shares Float |
5 (M) |
|
% Held by Insiders
|
26.1 (%) |
|
% Held by Institutions
|
30.9 (%) |
|
Shares Short
|
80 (K) |
|
Shares Short P.Month
|
123 (K) |
Stock Financials |
|
EPS
|
-4.81 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-1.79 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-19.1 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-18 (M) |
|
Levered Free Cash Flow
|
-16 (M) |
Stock Valuations |
|
PE Ratio
|
-1.52 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-4.08 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-2.9 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
